Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors

Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors

Predictive biomarkers of response to immune checkpoint inhibitors (ICI) help to identify cancer patients who will benefit from immunotherapy. Protein kinase, DNA‐activated, catalytic subunit (PRKDC) is an important gene for DNA double‐strand break (DSB) repair and central T‐cell tolerance. We aimed...

Full description

Bibliographic Details
Main Authors: Yu Chen, Yi Li, Yanfang Guan, Yingying Huang, Jing Lin, Lizhu Chen, Jin Li, Gang Chen, Leong Kin Pan, Xuefeng Xia, Ning Xu, Lianpeng Chang, Zengqing Guo, Jianji Pan, Xin Yi, Chuanben Chen
Format: Article
Language:English
Published: Wiley 2020-09-01
Series:Molecular Oncology
Subjects:
DNA‐PKcs
immune checkpoint inhibitors
PRKDC
tumor microenvironment
tumor mutation burden
Online Access:https://doi.org/10.1002/1878-0261.12739

Internet

https://doi.org/10.1002/1878-0261.12739

Similar Items